Same Indication

Nivolumab vs Rosuvastatin

Nivolumab vs Rosuvastatin: Overview

This comparison examines the pharmacological differences between Nivolumab and Rosuvastatin.

Mechanism of Action

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Rosuvastatin: Competitive inhibitor of HMG-CoA reductase.

Pharmacokinetics

Half-life: Nivolumab β€” 27 days; Rosuvastatin β€” 19 hours.

Chemical Properties

Molecular Formula: Rosuvastatin β€” C22H28FN3O6S.

Molecular Weight: Rosuvastatin β€” 481.5390 g/mol.

Type: Nivolumab β€” Antibody; Rosuvastatin β€” Small molecule.